Lakewood-amedex Biotherapeutics INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Lakewood-Amedex Biotherapeutics reported a Q1 loss but successfully listed on Nasdaq and raised $6.8 million in net proceeds to fund operations through 2026.